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1, INTRODUCTtON 
The glucose phosphorylacing enzyrntl glucokinasc 
(ATP:D-hexosWSphosplrorransferase, EC 2,7.1(l) 
plays a central role in regulating lucose metabolism in 
liver and pancreatic islets of Lange&ins [1,2]. The 
single glucokinase gent in the rat gcnome can be 
transcribed and proccsscd to yield several distinct 
species of rnRNA [3-51, The major glucokinase mRNA 
in liver has a size of 2,4 kb, as opposed to the major 
species in islets, which is 2.8 kb. Analysis of cDNA 
[4-81 and genomic [4,8,9] clones has revealed that the 
mature mRNAs are derived from 10 exons, and while 
both the liver and islet transcripts cl3ntain exons 2 
through 10, exon 1 is unique and is spl!ced in a tissue- 
specific manner. Recently, 3 additional variant 
glucokinase transcripts have been described thzi are ex- 
pressed in islets and islet cell lines [73, anterior pituitary 
cells and cell lines [S], solid insulinoma tumors [4], and 
liver [8]. The goal of the work described in this 
manuscript was to develop a system for producing large 
quantities of protein from both normal and variant 
glucokinase transcripts in order to begin to evaluate 
their physiological significance. 
Correspondence uddress: C.B. Newgard, Center for Diabetes 
Research, Gifford Laboratories and Department of Biochemistry, 
University of Texas Southwestern Medical Center, 5323 Harry Hines 
Blvd., Dallas, TX 75235, USA 
Published by Ekevier Science Publishers B. V. 
2. MATERIALS AND METHODS 
pression w-far pTrc99A 
Tk tmlerinl vector system chosen for these studirr is pTrc99A, a 
tlcrivntivc at” pKK.322, as described by Anrann et al. [lo]. This vector 
utilircs a Trp/Lnc promotcr to drive exprcrsion OF the ketcrolo~ous 
ycnc of interest. The plasmid contains the IaclQ repressor, which 
allows expression OF the hetcroloyous gene to bc tightly controlled by 
the presence or absence of IPTG. 
Insertion of the normal islet glucokinasc DNA (5,7) into the 
pTrc99A vector was facilitated by site-directed mutagenesis [I I], in- 
lroducing an Nco I site at the ATG start codon (the first of two in- 
frame AUG triplets encountered in the open readin’g frame of islst 
glucokinasc [4,5,7]) and a &WI HI site in the 3’ untranslated region, 
41 bp 3’ of the TGA stop codon. Introduction of the Nco site(muta- 
lion of the sequence AGATGC to CCATGG) results in a base change 
in the second codon leading to the conservative substitution of a 
valine for a lcucine in the translated product. This construct was 
designated pGKB1. 
To generate the liver specific glucokinase cDN& PCR amplifica- 
tion was carried out on liver poly (A”) RNA as previously described 
[7], using a 5’ oligonucleotide, S’ACGCGATCCTTTGCAACAC- 
TCAG C3’ from the unique 5’ untranslated region OF the 
liver glucokinase cDNA [6] and 3’ oligonucleotide 
5’ ACGGAATTCCCCTTGGTCC AATTGAG3’ that encompasses 
nucleotides 980-996 [7]; included in the oligonucleotide sequences are 
restriction sites (Barn MI and Eco RI) that facilitated cloning of the 
PCR products. An Ivco I site was introduced at the ATG start codon 
of this DNA, but without alteration of the second codon (mutation of 
AGATGG to CCATGG). This plastnid was designated pGKL1. 
The variant glucokinase cDNA transcript expressed in islets and 
anterior pituitary cells that has, the unique 5 ’ untranslated region and 
Nmterminal sequence associated with islet glucokinase cDNAs, but 
that also contains a 52-nucleolide deletion corresponding to the 3’ 
end of exon 2 [7] was subcloned by a strategy similar to that employed 
for construction of pGKB1. This plasmid was designated pGKB3. 
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Fig. I. Szhemntic a~mmary of cRNA constructs cxprcsscd in bacteria. The lop bar dcpic~s ~hc structure of the rat glusokinaxe gene [4,&g]. The 
gcnc is processed 13 yield distinct mRNA spcsirscontirining segments afthcpcnc ;\J indicated, in islrt andnntcrior pitultnrycelIs(the ri%h versions 
of thcsc wcrc cloned into bacterial vcctar pTrc99A IQ yield etwrtructs pGKBl and pCXB3) wxl liver (cenatrwr pGKLl and ~ciK.L.2)~ 
The variant glucokinarc cDNA clone from rat liver (81 that csntnins 
a ISI-bp insertion between cxans I and 2 of the normal transcript, as 
well as the same 52.bpdclction as found in the islct/nntcrior pituitary 
construct pGKB3 was subclonetl by introduction of the Nco I site ii-s 
dcsctibcd for pGKLI, and the resultant plnsmicl was dcsignrted 
pGKL2. 
The glucokinasc cDNA varhnis used in this study arc summnrixcd 
schematically in Fig. I. 
2,2, Expression oJ IKE GA’ isoforttrs in bacleria und preparation of 
exmcts 
Competent E. co/i, strain JMIOP were transformed with the con- 
str!:cts &scribed above and plated on LB/ampicillin to select for 
transformants. For expression studies, 2.ml cultures were grown for 
G h in LB/ampicillin and diluted I:40 into duplicate sterile tubes con- 
taining IO ml LB/iimpicillin. Cultures were allowed to grow to log 
phase (0.3 OD at 600 nM) at which time IPTC (final concentration of 
I mM) was added to one of the duplicate cultures (induced) while the 
other received no additions (uninduced), Both cultures were then 
grown overnight at 37°C with shaking. 
The overnight cultures were centrifuged at 8OOOxg and the pellets 
brought up in l/IO volume of GTE (50 mM &~cose. 10 mM EDTA, 
25 rnM Tris-HCI, pM 8.0) with 3 mg/ml lysotyme, left at room 
temperature for S min. transferred to ice, and supplemented with 
PMSF (0.2 mM), Nonidet-40 (O.l@Io), DTT (1 mM). and NaCl (0.25 
M). The samples wrre then immediately sonicated and cleared by a 10 
min spin in a microcentrifuge at 4°C. The protein concentration was 
measured using Bradford’s reagent (Bio-Rad). 
2.3. Preporation oJ region-specific anripepride unribodies and 
Western blot analysis 
TWO synthetic polypeptides were prepared (courtesy of Sarah 
Stadley and Dr. Lilah Gicrasch, University of Texas Southwestern 
Medical Center) one (GK-1, LDDRARMEATKKEK) with sequence 
corresponding to the N-terminal 15 amino acids of the islet 
glucokinase isoform [4.5,7], and the other (GK-2, KLHPSFKER- 
FHASVR) corresponding to amino acids 414-428 encoded by con- 
structs aCiKL1. aGKL2 and aC;KBl. but nor nGKB3. Thr ncotidrs . 
were couplctl to PPD (purified pratcln derivative of tubfrcuiin) with 
ylurnrnldchydc and used to raise anti-peptide antibodies in White NW 
Zealand rabbits as previously described (71, The pnlyclonal antiserum 
against GK-1 (specific for the islet isoform of glucokinasc) is 
designated U343 and that against GK-2 (com~norr region) is termed 
V980, For Western blot analysis, the polyclonal scrn wcrc affinity- 
purified, first by passage over a Staphylococcus protein A column, 
followed by passage over a column containiny the pcptide to which 
the scrn were r&cd, using protocols and reagents supplied by Picrcs. 
Electrophoresis of bacterial extracts, transfer to nitroccllulose and 
immunoblotting were carried out as described [7], except rhst washing 
of blots after addition of the secondary antibody was done with 5% 
instead of 2% Tween-20, 
2.4. Ghrcokinase enzynm~ic ussuys 
Assays were carried out at 37”C, in a reaction buffer consisting of 
0,l M Tris, pH 7.2, 5 mM ATP, IO mM M&12, 100 mM KCI, I mM 
dithiothreitol, §OOaM NAD and glucose, in a range of concentrations 
from 0.5 to 50 mM. The assay buffer also contained 2 aI (2.5 U) of 
glncose-6-phosphate dchydrogcnase, prcparcd from Leuconosroc 
tnesenreroitles (Bochringer Mannheim) 1121. The reaction was in- 
itiated by addition of 2Oyl of the cleared supernatant from the crude 
bacterial extract and change in absorbance at 340 nm was monitored 
over IO min. Addition of bacterial extracts to the reaction buffer con- 
taining NADH revealed no degradative effect of the extract on 
NADH. 
3. RESULTS 
3.1. Expression of glwokinase variants in E. co/i 
Bacterial expression of the 4 glucokinase constructs 
shown in Fig. 1 was evaluated by Western blot analysis. 
66 - 
66 - 
45 - 
31 - 
Antibody 
U343 + peptide 
66 - 
45 - 
Antibody 
V980 -b Peptide 
Fig. 2. Western blot analysis of glucokinase variants expressed in bacteria. Left: bacteria containing the variant constructs were grown in the 
prct’ence (+) or absence (- ) of IPTC. Western blot analysis was carried out as described in Section 2 with immunopurified U343 (top panel) or 
with I.1343 after preincubation with pcptide Gk-1 (lower panel). Right: Western blot analysis was carried out as in panel A, except with 
immunopurified V980 (top panel) or with V980 after preincubation witlr peptide GK-2 bottom panel). Positions of molecular mass standards 
(values in kDa) are indicated on the left of the figures. 
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gluturaiclclrydc Pi#iny of the ye1 prisr to blor ErUr&cf, In 
an &?‘ort to transfer the pcp~idc as il large, rrors-link& 
complex; nnd (3) rne~~~ol~~ abeling wnd immuna- 
grceipiratiQn, carried out both with the srandnrll wnlt 
spccinlixfd +2lc~:fraphareaiis tcchniqucs dcscribcd f\bovc, 
De:;yitc thin extensive un,?lyain, WC wcrc unable to dcrecr 
cxprcssiori nf the gcpticlc predicted by pCXD3, a rcault 
in keeping with ita npparrnl: nb~ncl: fram cucxrryotie 
cells in which ita mRNA ix fc~und [tl. It aho~ld btr na~d 
that the constructs wcrc verified by sequencing prior to 
cxprcasion stuclics. Also, cxprexniun of each of the 4 
conftru~ts in bacteria @w? rise to detecte\blc RNA 
franscriprm (data not shown). 
Fig. 3 shows acrivicy measurements performed (311 
bncterial extracts expressing rhi: variant glucakinasc 
cDNAs. Extrncte at” bacterial culturc.s grown in the 
abacncc 0f the transcriptional induecr IP’PG exhibit r? 
low rate caP glucose phosphorylatisn thnt is independent 
sf assay @Il\rcoscconccntrntion over the range l-50 mM. 
This low background activity, which is likely due to 
bacterial hexokinase, is also present in culrurcs contain- 
ing the pTrc99A plasmid without a cBNA insert (data 
not shown). In the presence of IPTG, a glucosc- 
dependent glucokinase activity is clearly seen that 
reaches a maximum of 200 U/g protein for plasmid 
pGKB1 (7.5-fold above background; Fig. 3, top) and 
2564 U/g protein for plasmid pGKL1 ($5.fold above 
background; Fig. 3, middle) at 50 mM glucose. Dcn- 
sitornetric scanning of the blot in Fig. 2(right) reveals 
that the pGKL1 (liver) protein is present at 6,Sfold 
greater abundance than the pGKBl (islet) protein when 
assayed with the common antibody VOW indicating 
that the lo-fold difference in activity is largely a func- 
tion of the amount of glucokinase protein expressed. 
Measurement of glucose phosphorylating activity 
was also performed on extracts of bacteria containing 
plasmids pGKL2 and pGKB3. For construct pCXL2, 
glucose phosphorylating activity was found to be at the 
low background level in the presence or absence of 
lPTG (Fig. 3, bottom) in spite of the fact that the level 
of expression of the pGKL2 protein product was similar 
to pGKBI. Not surprisingly, no high K,,, glucose 
phosphorylating activity was detected in bacteria 
transformed with pGKB3 (data not shown). 
Fig. 3. Glucose phosphorylating activity in bacterial cultures 
expressing variant glucokinase cDNAs. For all panels, crude extracts 
were prepared from bacteria grown in the presence(m) or absence (0) 
of lPTG and assayed for glucose phosphorylating activity as 
described in section 2. Top: activity in extracts prepared from bacteria 
expressing plasmid pGKBI. Middle: activity in extracts prepared 
from bacteria expressing plasmid pGKL 1. Bottom: activity in extracts 
prepared from bacteria expressing plasmid pGKL2. Data are 
expressed as the mean activities h SEM in 3 independent bacterial 
extracts. 
Blueabinewf has been nrcrib~d tt crnrrul r&2 in the 
rcBulntiun of hcputlc end irlet dell glucaxc 
nrctrbeliam, FWcrttly, work from acvicral Mxxatarica 
[3-91 ha4 resulted in rhc idcntifieMan n? $ distinct 
variant glueakinaxc mRNA tgeeitz% exprc~~l in ixlets, 
iiv~r and nntcriar piluitary. In the CiirTcnt study, we 
lravc begun to uddrcsa the phynialsgicsl rignificancc of 
the multiple glucskinaxc gene prtxluets by preparing 
four of thctc naturally occurring trarrseripts tls cDNA 
and expressing them in baetcria. Absent from this 
group Lo a glucokinnrc cBNA dc$eribcd by Magnuson 
and Shelton (41 cloned from I solid insulinsma tumor 
library that contains :r 51.bp dclcrion at the 5’ end af 
cxan 4, Ihat would bc designntcd clone pCXB2 using 
rcccntly suggcstcd nemcnelaturc [ 131. This clone wan 
not included in the prcscnt study because xtensive 
analysis of islet, anterior pituitary, AtT-20 and in- 
oulinomn ccl1 line RNA in our laboratory by polymcrnse 
chain reaction amplification ancl nuelcotide scqucneing 
failed to identify any clones containing this deletion [7]. 
Expression of construers gQKLl and pGKBl resulted 
in a glucose-dependent, glucokinasc-like activity 
7.5.fold and 45.fold, respectively above the baek- 
ground bacterial glucose phospherylation activity when 
assayed at 50 rnM glucose. The greatly enhanced liver 
glucokinaac activity is in keeping with the more efficient 
expression of the liver isoform protein as measured by 
Western blot analysis, One possible xplanation for the 
enhanced expression of the liver isoform is codon 
usage, since the codon GTG (Valinc), which is found at 
the second position of the islet glueokinasc onstructs 
pGKB1 and pGKB3 is rarely found in bacterial genes, 
and results in approximately 3-fold less expression 
when inserted into test genes compared to the GCT 
(Alanine) codon 1141, found at position 2 in the liver 
glucokinase constructs pGKL1 and pGKL2, Other fac- 
tors may also be at work, as suggested by comparison of 
the two liver constructs pGKL1 and pGKL2. While the 
latter is expressed at a level approximately equal to islet 
glucokinasc, it is clearly less efficiently expressed than 
pGKL1, despite the fact that the two constructs hare 
the GCT second codon. This discrepancy might be ex- 
plained by the fact that the 151-bp insertion in pGKL2 
contains two AGA codons for arginine [S] whose cor- 
responding tRNAs are extremely rare; genes containing 
this codon at their 5’ end are expressed with reduced ef- 
ficiency 1151. 
The pGKLZ gene product does not encode an en- 
zymatically competent glucokinase protein. In this 
naturally occuring mRNA, a 151 bp insertion in- 
troduces a total of 87 unique amino acid residues 
relative to pGKL1. Of these, 50 residues are encoded by 
the insert itself and 37 residues come from nucleotides 
derived from a region of exon 2 that is shared with 
pGKL1, but that is read in a different frame as a conse- 
quenee of ths infcrtiun 1%). Intcrcathi~ly, althouyh 
pGKbl eontninr 51511 nuclcotidc deletion csrrcsgxxxling 
fothc 3’ end afcxen 2, the putative bindingxitctt forthc 
xubWutcs ATP WI glucnrc (6) arc left untcM~cd, aug- 
@sting that important functianal domains that dcrcr- 
mint activity arc intact. It should bc natcd, howcvcr, 
that the 17 altctcd amino neidx arc found just 8 rcsidueri 
to the N-trrminnl xidc of the propaxed h7’P binding 
site; furthcrmarq thr inacrtcd scguencc is highly 
hydrophobic compa~cd t8r the sequence of the active 
@ucekinasc ixafsrma. Although the exact structural 
pcrturbatisns introtluccd by the insertion arc currently 
unknown, it appear% that these altcrntionr are sufficient 
to ~auac the variant protein to bc nonfunctional as a 
glucose phenphorylating enzyme. While vfc present no 
proof of expression of the 800 Da pcptidc predicted by 
the alternate transcript of islets and anterior pituitary, 
pGKl33, we would not predict that i: can encode an a~- 
rive enzyme, since the open reading frame in this 
transcript crfiiinates upstream of the region contaifling 
the putative ATP and glucose binding sites. 
The physiological role of the variant products of the 
glucokirrasc gene remains an open question, since 
although the transcripts are naturally occurring, they 
do not appear to result in efficient production of pro- 
tein in mammalian cells. Immunobtotting with a 
polyclonnl antibody raised against the purified liver 
glueokinasc protein detects only a single band of iden- 
tical molecular weight in liver and islets [3,14], Further, 
extensive efforts aimed at demonstrating the expressicen 
of the 58 amino acid peptidc predicted by constru;:t 
pGKB3 in islet or anterior pituitary cells and cell lines 
have thus far been unrewarding [7]. It should be noted, 
however, chat levels of the variant glucokinasc mRNA 
in liver are regulated by fasting and rcfecding [S], sug- 
gesting that there may be physiological conditions that 
lead to accumulation of one or both of the variant pro- 
teins. Finally we considered the possibility that the 
variant constructs might encode proteins capable of 
regulating glucose phosphorylation, but found that 
mixing of either variant with pGKB1 or pGKL1 or with 
crude extracts of !iver or islets gave strictly additive ef- 
fects (data not shown). 
While glucokinase is not classically thought of as an 
allosterically regulated enzyme (in contrast to hexo- 
kinase, which is potently inhibited by glucose-&phos- 
phate), evidence for regulation of glucokinase activity 
has recently begun to accumulate. Van Schaftingen and 
co-work,ers have described a fructose phosphate- 
sensitive glucokinase regulatory protein [ 171. In- 
terestingly, this regulatory system appears to be less 
active in islets than in liver [18]. Other ligands, such as 
long-chain acyl CoAs [ 191 or alloxan [20], or enzymes 
of covalent modification, such as protein kinase A [al] 
have been implicated as potential regulators of gluco- 
kinase activity, but have never been assayed in a com- 
parative study of the liver and islet enzymes, in part 
51 
brcnuxe of the Jiff’iculticx inhcrcnr in purifying rhc Iat- 
ter pratcin. The devdapmcnt of sy4tcm far svcrrxprex- 
aion of islet (this wmk) ml livrr (this work uncl (21]) 
glucakinarca now pravidcs a fanvcnienr ancl abundant 
source aT the IWO protcinx tbr the purpmss d purificn- 
tion and careful cvnluillim of their kinetic and 
rcyulatory propertics. 
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